Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Target Price
The average target price of EYE.AX is 0.39 and suggests 169% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc